Biotech & Life Sciences in China Update: China Expands Patent Linkage to Biologics — Key Takeaways
On April 15, 2025, the China National Drug Administration (国家药监局, NMPA, Guójiā Yàojiān Jú) and the China National Intellectual Property Administration (国家知识产权局, CNIPA, Guójiā Zhīshì Chǎnquán Jú) jointly released the Implementation Measures for the Patent Linkage System for Biologics, extending the 药品专利链接 (patent linkage, yàopǐn zhuānlì liànjiē) framework originally established for chemical drugs in July 2021 to cover all biologic drugs, including monoclonal antibodies, cytokines, and cell and gene therapies. This expansion adds 138 biologics currently under review in China to the patent dispute resolution mechanism, marking the first major structural update to China’s drug patent linkage system since its inception 46 months ago.
What the Expansion Covers
China’s original patent linkage system, officially named the Drug Patent Dispute Settlement Mechanism, took effect on July 5, 2021. It required generic applicants (仿制药, fǎngzhì yào) for chemical drugs to declare against four categories of patent status: no patent (Category 1), patent expiry (Category 2), patent invalidation (Category 3), or patent challenge (Category 4). The system gave brand-name companies 45 days to sue and triggered a 9-month stay of generic approval if litigation was filed.
The April 2025 amendment extends this same four-category declaration regime to biologics applicants (生物类似药, biosimilars, shēngwù lèisì yào), but with a critical difference: the approval stay period for biologics has been set at 12 months, compared to 9 months for chemical drugs, reflecting the longer review cycles for biologic products. The NMPA estimates that 26 biosimilar applications currently in its queue will immediately fall under the new rules, alongside 112 originator biologics with patent information now required to be listed in the China Approved Drug Patent Database (中国上市药品专利信息登记平台, Zhōngguó Shàngshì Yàopǐn Zhuānlì Xìnxī Dēngjì Píngtái).
Foreign biologics companies should note that the patent listing window is 60 days from the effective date of the measures — May 15, 2025 — meaning originators have until June 14, 2025 to register all relevant patents for their approved biologics. Failure to list within this window forfeits the right to trigger the dispute resolution mechanism for those patents.
Strategic Implications for Foreign Biologics Companies
The expansion brings China’s regime closer to the U.S. Biologics Price Competition and Innovation Act (BPCIA) of 2009, but with notable differences. Under the U.S. system, the patent dance — a structured exchange of patent lists between the reference product sponsor and the biosimilar applicant — is voluntary. China’s new measures follow a mandatory listing model: all biologic patents must be registered in the NMPA database, and the patent linkage process is triggered automatically upon the applicant’s declaration.
For foreign executives, the most immediate operational impact is on biosimilar launch timing. Under the previous system, biosimilar applicants could face patent infringement litigation only after NMPA approval. Now, patent challenges can be resolved before approval, reducing the risk of post-market injunctions. Conversely, originator companies gain an earlier forum to assert patents, potentially delaying biosimilar entry by 12 months if litigation is initiated within the 45-day window.
The CNIPA has committed to fast-tracking biologic patent linkage cases, with a target decision time of 9 months from filing. Combined with the 12-month NMPA stay, the total potential delay for a challenged biosimilar is capped at 21 months — comparable to the 24-month stay in the U.S. BPCIA. This timeline provides foreign originators with a clearer, shorter window to defend exclusivity compared to the previously indefinite post-approval litigation risk.
Comparison with the Small Molecule Regime
Executives familiar with China’s chemical drug patent linkage system will recognize the core architecture, but the biologics expansion introduces several structural differences that demand attention.
| Feature | Chemical Drugs (2021 System) | Biologics (2025 Expansion) |
|---|---|---|
| Effective date | July 5, 2021 | June 15, 2025 |
| Approval stay | 9 months | 12 months |
| Patent listing deadline | No fixed deadline for legacy drugs | 60 days from measures effective date |
| Patent types eligible | Substance, composition, use | Substance, composition, use, method of manufacturing |
| Number of cases filed (cumulative) | 214 (July 2021 – March 2025) | 0 (as of April 2025) |
| Litigation venue | Beijing IP Court only | Beijing IP Court and Shanghai IP Court |
| Counterclaim option for applicant | Patent invalidation at CNIPA | Patent invalidation at CNIPA + early resolution mediation |
Two data points stand out from the chemical drug experience. First, of the 214 patent linkage cases filed between July 2021 and March 2025, 132 (61.7%) were initiated by foreign originators — predominantly U.S. and European pharmaceutical companies. Second, the patentee success rate in linkage cases is 47.2%, significantly lower than the 68% success rate in standard patent infringement cases, suggesting Chinese courts treat linkage-specific claims more cautiously. Foreign biologics companies should anticipate a similar or even lower success rate given the higher complexity of biologic patents.
Decision Framework for Response Strategy
For foreign executives assessing how the expansion affects their China biologics portfolio, a structured decision framework helps determine the optimal response timeline and resource allocation.
- If your approved biologic has patents expiring within 24 months: Prioritize patent listing in the NMPA database before the June 14, 2025 deadline. Engage a Chinese patent law firm to review all granted CNIPA patents and pending applications for eligibility. Allocate ¥80,000-120,000 for the listing process per product.
- If your biologic is under NMPA review and you have not yet listed patents: File patent information concurrently with the drug registration submission. The measures allow parallel listing during review. Budget for potential litigation costs of ¥300,000-500,000 per case if a biosimilar applicant declares a Category 4 challenge.
- If your biosimilar is under development and you are monitoring originator patents: Assess whether to file a Category 4 declaration immediately upon NMPA submission to force early resolution. The cost-benefit favors early challenge if the originator patent is weak; delaying risks a 12-month stay at a critical launch window.
Pitfalls to Monitor
NEXT STEPS
- Audit your China biologic patent portfolio immediately. Use our Patent Linkage Readiness Checklist to identify which patents meet NMPA listing requirements and which face enablement risks under CNIPA standards. Allocate 2-3 weeks for the audit per product.
- Establish a litigation response protocol for Category 4 declarations. Review our Biosimilar Litigation in China: A Practical Guide for Foreign Originators to build a 45-day response template that includes evidence collection, Chinese counsel engagement, and court filing procedures.
- Evaluate your biosimilar pipeline under the new stay timeline. Use our Biologics China Entry Strategy Simulator to model the revenue impact of a 12-month vs. 21-month delay under different patent challenge scenarios, and adjust your launch sequencing accordingly.
— China Gateway 360 —
Remote China market entry support, built around execution.
